Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-04457845, FAAH inhibitor · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Cohort 1 (N=10) | EXPERIMENTAL | Placebo-controlled, escalating multiple doses of 0.5mg per day for 14 days. |
| Cohort 2 (N=10) | EXPERIMENTAL | Placebo-controlled, escalating multiple doses of 1mg per day for 14 days. |
| Cohort 3 (N=10) | EXPERIMENTAL | Placebo-controlled, escalating multiple doses of 4mg per day for 14 days. |
| Cohort 4 (N=10) | EXPERIMENTAL | Placebo-controlled, escalating multiple doses of 8mg per day for 14 days. |
| Name | Type | Description |
|---|---|---|
| PF-04457845, FAAH inhibitor | DRUG | Oral solution of 0.5mg given once daily for 14 days. |
Inclusion Criteria: * Healthy male and/or female subjects (of non childbearing potential) between the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and puls...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Fresenius Medical Care AG Sponsored ADR | FMS | 2 | PHASE3 | Dialysis |
| AstraZeneca PLC | AZN | 1 | PHASE2 | AZD4144 |
| CalciMedica, Inc. | CALC | 1 | PHASE2 | Auxora |
| Talphera, Inc. | TLPH | 1 | N/A | Undisclosed |
| SeaStar Medical Holding Corporation | ICU | 2 | - | Undisclosed |
| Collegium Pharmaceutical, Inc. | COLL | 1 | - | Flozin |
PF-04457845 is an investigational small molecule being studied for acute pain, chronic pain, and osteoarthritis of the knee. It has been evaluated in healthy volunteers and in patients with knee osteoarthritis. The drug is not approved and remains in clinical development.
PF-04457845 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. The company has sponsored clinical trials of the drug in healthy volunteers and in patients with osteoarthritis of the knee.
PF-04457845 has completed Phase 1 and Phase 2 clinical trials. The most advanced study was a Phase 2 trial in patients with osteoarthritis of the knee. The drug is investigational and has not been approved by regulatory authorities.
PF-04457845 has been studied in three completed trials: NCT00836082, a Phase 1 multiple dose trial in healthy volunteers; NCT00918164, a Phase 1 bioavailability and food effect study; and NCT00981357, a Phase 2 trial in patients with osteoarthritis of the knee.
PF-04457845 is the primary name used in clinical trial records for this investigational drug. No alternative names have been reported in the available clinical trial information.